Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy

Graziela Z. Dal Molin; Kohei Omatsu; Anil K. Sood; Robert L. Coleman

doi:10.1177/1758835918778483

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy

Graziela Z. Dal Molin, Kohei Omatsu, Anil K. Sood, Robert L. Coleman

Gynecological Oncology & Reproductive Medicine

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 and PARP3 enzymes. Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma, with both BRCA-mutated (germline and somatic) and with homologous recombination deficiency (HRD). Rucaparib as a maintenance treatment showed increased progression-free survival in patients with ovarian carcinoma who achieved a response to platinum-based chemotherapy, with an acceptable safety profile. The approval of this drug, along with the companion diagnostic FoundationFocus CDxBRCA test represents an important new therapeutic option in the treatment of ovarian cancer. This article reviews the mechanisms of action, safety, pharmacokinetics and pharmacodynamics and indications for use of rucaparib as well as future trials.

Original language	English (US)
Journal	Therapeutic Advances in Medical Oncology
Volume	10
DOIs	https://doi.org/10.1177/1758835918778483
State	Published - Jan 1 2018

Keywords

BRCA
PARP
PARP inhibitors
Rubraca
ovarian cancer
platinum-sensitive ovarian cancer
rucaparib

ASJC Scopus subject areas

Oncology

Access to Document

10.1177/1758835918778483

Cite this

@article{15f85fddd6f04316bf9f0e7d9531a10f,

title = "Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy",

abstract = "Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 and PARP3 enzymes. Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma, with both BRCA-mutated (germline and somatic) and with homologous recombination deficiency (HRD). Rucaparib as a maintenance treatment showed increased progression-free survival in patients with ovarian carcinoma who achieved a response to platinum-based chemotherapy, with an acceptable safety profile. The approval of this drug, along with the companion diagnostic FoundationFocus CDxBRCA test represents an important new therapeutic option in the treatment of ovarian cancer. This article reviews the mechanisms of action, safety, pharmacokinetics and pharmacodynamics and indications for use of rucaparib as well as future trials.",

keywords = "BRCA, PARP, PARP inhibitors, Rubraca, ovarian cancer, platinum-sensitive ovarian cancer, rucaparib",

author = "{Dal Molin}, {Graziela Z.} and Kohei Omatsu and Sood, {Anil K.} and Coleman, {Robert L.}",

note = "Funding Information: RLC is supported by CPRIT RP120214, the Ann Rife Cox Chair in Gynecology, Judy Reis/Albert Pisani, and the MD Anderson ovarian cancer research fund. Other parts of this work are supported by R35 CA209904, the Frank McGraw Memorial Chair in Cancer Research, the American Cancer Society Research Professor Award and the Blanton-Davis Ovarian Cancer Research Program. Funding Information: RLC has clinical research funding from Merck, AstraZeneca/Medimmune, Genentech/Roche, Novartis, Clovis Oncology, Abbvie, and Janssen Publisher Copyright: {\textcopyright} The Author(s), 2018.",

year = "2018",

month = jan,

day = "1",

doi = "10.1177/1758835918778483",

language = "English (US)",

volume = "10",

journal = "Therapeutic Advances in Medical Oncology",

issn = "1758-8340",

publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Rucaparib in ovarian cancer

T2 - an update on safety, efficacy and place in therapy

AU - Dal Molin, Graziela Z.

AU - Omatsu, Kohei

AU - Sood, Anil K.

AU - Coleman, Robert L.

N1 - Funding Information: RLC is supported by CPRIT RP120214, the Ann Rife Cox Chair in Gynecology, Judy Reis/Albert Pisani, and the MD Anderson ovarian cancer research fund. Other parts of this work are supported by R35 CA209904, the Frank McGraw Memorial Chair in Cancer Research, the American Cancer Society Research Professor Award and the Blanton-Davis Ovarian Cancer Research Program. Funding Information: RLC has clinical research funding from Merck, AstraZeneca/Medimmune, Genentech/Roche, Novartis, Clovis Oncology, Abbvie, and Janssen Publisher Copyright: © The Author(s), 2018.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 and PARP3 enzymes. Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma, with both BRCA-mutated (germline and somatic) and with homologous recombination deficiency (HRD). Rucaparib as a maintenance treatment showed increased progression-free survival in patients with ovarian carcinoma who achieved a response to platinum-based chemotherapy, with an acceptable safety profile. The approval of this drug, along with the companion diagnostic FoundationFocus CDxBRCA test represents an important new therapeutic option in the treatment of ovarian cancer. This article reviews the mechanisms of action, safety, pharmacokinetics and pharmacodynamics and indications for use of rucaparib as well as future trials.

AB - Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 and PARP3 enzymes. Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma, with both BRCA-mutated (germline and somatic) and with homologous recombination deficiency (HRD). Rucaparib as a maintenance treatment showed increased progression-free survival in patients with ovarian carcinoma who achieved a response to platinum-based chemotherapy, with an acceptable safety profile. The approval of this drug, along with the companion diagnostic FoundationFocus CDxBRCA test represents an important new therapeutic option in the treatment of ovarian cancer. This article reviews the mechanisms of action, safety, pharmacokinetics and pharmacodynamics and indications for use of rucaparib as well as future trials.

KW - BRCA

KW - PARP

KW - PARP inhibitors

KW - Rubraca

KW - ovarian cancer

KW - platinum-sensitive ovarian cancer

KW - rucaparib

UR - http://www.scopus.com/inward/record.url?scp=85054602211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054602211&partnerID=8YFLogxK

U2 - 10.1177/1758835918778483

DO - 10.1177/1758835918778483

M3 - Review article

C2 - 29977351

AN - SCOPUS:85054602211

SN - 1758-8340

VL - 10

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

ER -

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this